It’s so refreshing to have someone who walks in the same shoes as other rare parents! We are grateful for the work you’re doing to further the research for a new treatment for our rare disorders!
A devastating diagnosis for her 10-year-old son compelled Alltrna CEO Michelle Werner to leave her career in pharma, where she helped advance new immunotherapies that transformed cancer treatment, to usher in a new drug development paradigm in rare diseases. Alltrna is leading the development of new tRNA medicines that may be able to treat patients across hundreds, maybe even thousands, of life-threatening conditions, rather than tackling each individual disease one at a time.? But we can’t do it alone. In this Fortune article, Michelle shares her journey and calls upon patient groups, clinicians, regulators and others in pharma to join her on her quest to double survival rates for rare diseases—many of which overwhelmingly affect children. "For these young patients, doubling survival isn’t just about extending life; it’s about giving them a chance to grow up, to experience milestones their families once feared they’d never see." Read the article here: https://lnkd.in/gkX7Ya59 #tRNA #RNA #tRNAmedicines #tRNAbiology #rarediseases #raredisease #StopCodonDisease #geneticmedicines